How we read the evidence.

Scope of this collection

The library contains 49 selected study records covering tirzepatide, BPC-157, and research on KLOW’s components. It includes human trials, uncontrolled reports, and animal or cell experiments. This is a structured evidence collection, not a systematic review or a claim to include every available study.

The current expansion searches Europe PMC publications and ClinicalTrials.gov records through September 8, 2026, using compound names and aliases. Searches are paginated and retrieval failures are recorded. Search matches include irrelevant mentions, reviews and duplicate analyses; a search-result count is not a count of relevant studies. Screening and extraction of the broader inventories remain in progress.

What the source labels mean

Each displayed field identifies its source location and whether it comes from an abstract, full report, methods publication, protocol, supplement or posted registry results. Source depth can differ within one study. Planned protocol details remain separate from observed findings. The literature search cutoff is 2026-09-08. Extraction and source reconciliation continue after that date; the cutoff does not mean every record was reviewed on that day.

There are currently 52 explicitly flagged field gaps across the selected records. A field without a gap flag is not proof that the study or the entire literature has been completely reviewed. Open a field’s source details to inspect the specific basis for its summary.

Primary reports and supplements

The original four records used primary reports, registered protocols and supplied supplements. Later records use accessible publisher or repository full texts, primary abstracts and registry results as labeled. When full text is inaccessible, the record retains that limitation; an abstract is not silently treated as a complete paper.

Supplementary material can change interpretation of an endpoint, analysis population or regimen. We retain source-specific corrections and contradictions, including distinctions between treatment discontinuation and study withdrawal. A corrected result replaces the erroneous value; unexplained discrepancies remain disclosed rather than resolved by assumption.

Trials without published results

A registry describes a planned or conducted study. Recruitment status, enrollment and intervention descriptions do not demonstrate efficacy or safety. “Completed” does not mean results are posted, and a paper may exist before registry results are posted. Registry searches here cover ClinicalTrials.gov, not every national registry. Statuses are dated snapshots.

Protocols, mechanisms & pairings

Every compound profile includes a dose and frequency reference. “Community reference” records an attributed example or reported practice pattern; it is not a recommendation, a validated standard, or evidence of safety or effectiveness. “Approved label” applies only to the named product, population and indication. “Study reference” identifies a selected population-specific research regimen. Unresolved identities and unsupported human amounts remain explicitly unverified.

Amounts stay attached to route, formulation, frequency and duration. AxonRep does not convert mg, mcg or IU into syringe units because product concentrations vary and conversion errors can cause large dosing mistakes. Study durations are not automatically repeatable cycles. The September 27, 2026 comparison of saved PeptideDosages and Peptidepedia material adds source-specific alternatives and exact-ratio stack examples. Main pages, subpages and vial-size variants from a publisher are one source family, not independent confirmations. Conflicting amounts are not averaged, and topical, oral, injected, animal and product-label doses are kept separate.

Combination reports, receptor overlap, and preclinical findings do not by themselves establish a beneficial pairing. Route, formulation and cointerventions matter. Ophthalmic thymosin beta 4, recombinant NL005, and TB-500 fragments are not treated as interchangeable products. GHK is distinguished from copper-bound GHK.

Keep missing information missing

“Not reported in abstract” describes the source inspected. It does not mean the information is absent from the full paper. Missing safety reporting is not evidence of safety. A separately labeled community reference never fills a gap in a clinical study or supplies instructions for another formulation.

Compare the question before the number

Populations, comparators, outcome definitions, follow-up and statistical methods belong beside the results. A comparison table is not a head-to-head trial. Event counts, affected-participant counts and events per patient-year are different measures. Primary, secondary and exploratory outcomes remain distinguishable, including when the primary endpoint was not met.

KLOW search boundary

Searches included KLOW and the named BPC-157, TB-500/thymosin-beta-4, GHK-Cu and KPV combination. No exact four-component treatment study has been verified in the screened material. This does not establish that none exists. An unrelated registry match containing a text typo was excluded. Blend identity follows the project reference, not a verified standard formulation; component studies are not blend studies.

Editorial transparency

This collection is assembled with AI assistance. Source extraction and technical checks do not constitute clinical validation. AxonRep provides information, not medical advice or individualized treatment plans. Changes must preserve source attribution, population and relevant limitations. The site remains excluded from search indexing while publication review continues.